TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Omeros ( (OMER) ).
On November 25, 2025, Omeros Corporation completed a significant transaction with Novo Nordisk, granting the latter exclusive global rights to develop and commercialize zaltenibart (OMS906), a promising MASP-3 inhibitor. Omeros received an upfront payment of $240 million and is eligible for up to $2.1 billion in milestone payments and royalties. This deal allows Novo Nordisk to advance zaltenibart as a potential best-in-class treatment for rare blood and kidney disorders, while Omeros retains rights to its MASP-3 small-molecule program. The transaction also enabled Omeros to repay its senior secured term loan and is expected to support its operations and future product launches.
The most recent analyst rating on (OMER) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Omeros stock, see the OMER Stock Forecast page.
Spark’s Take on OMER Stock
According to Spark, TipRanks’ AI Analyst, OMER is a Underperform.
Omeros faces significant financial instability with no revenue and high debt, which heavily impacts its score. Technical indicators suggest some potential for short-term recovery, but poor valuation and ongoing losses are concerning. The company’s strategic focus on drug development and partnerships offers some optimism, but financial recovery is crucial for improvement.
To see Spark’s full report on OMER stock, click here.
More about Omeros
Omeros Corporation is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class small-molecule and protein therapeutics for both large-market and orphan diseases. The company emphasizes complement-mediated diseases, cancers, and addictive or compulsive disorders. Its lead MASP-2 inhibitor, narsoplimab, is under regulatory review for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy.
Average Trading Volume: 3,501,328
Technical Sentiment Signal: Buy
Current Market Cap: $687M
Find detailed analytics on OMER stock on TipRanks’ Stock Analysis page.